CONCORDBIO Concord Biotech Q4 FY26 results (Jan–Mar 2026) and concall
Concord Biotech faced a challenging FY26, reporting significant revenue degrowth across API and formulation segments due to geopolitical headwinds, supply chain disruptions, and regulatory delays, leading to a 12% full-year revenue decline and 30% PAT reduction. Despite these challenges, the company strengthened its regulatory compliance, commenced operations at its injectable facility, and maintained a zero-debt balance sheet with over INR 414 crores in cash. Management anticipates a stronger FY27 with growth exceeding historical rates, driven by new product launches and improved market condi
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 24.2%, net profit down 36.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 | 247 −20% | 278 +14% | 326 −24% |
| EBITDA | 137 | 98 | 190 | 61 | 91 −34% | 102 +4% | 122 −36% |
| Net profit | 99 | 74 | 142 | 43 | 63 −36% | 68 −8% | 90 −37% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
